Dare Bioscience, Inc. (DARE) shareholders
Close on Nov 13, 2026Market cap $10.05MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| L1 Capital Global Opportunities Master Fund, Ltd. | 2,028,885 | 9.99% | 13G (passive) | Aug 17, 2026 |
| Lind Global Fund III LP Joint filing with Lind Global Partners III LLC (5.65%), Easton Jeff (5.65%) | 1,094,890 | 5.65% | 13G (passive) | Aug 17, 2026 |
| Law Custodial Inc. | – | – | 13G (passive) amendment | Dec 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DARE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 640,877 | 4.19% | $1.35M | +178,572 | 0.00% |
| Geode Capital Management, LLC | 140,093 | 0.92% | $295.64K | −37,746 | 0.00% |
| US Bancorp \de\ | 120,920 | 0.79% | $255.14K | +29,550 | 0.00% |
| Vanguard Fiduciary Trust Co | 91,269 | 0.60% | $192.58K | +25,331 | 0.00% |
| BlackRock, Inc. | 64,248 | 0.42% | $135.56K | +47,277 | 0.00% |
| State Street Corp | 47,415 | 0.31% | $100.05K | +23,900 | 0.00% |
| Jane Street Group, LLC | 36,092 | 0.24% | $76.15K | New | 0.00% |
| Northern Trust Corp | 34,209 | 0.22% | $72.18K | +18,778 | 0.00% |
| Hrt Financial LP | 22,430 | 0.15% | $47.00K | New | 0.00% |
| Virtu Financial LLC | 15,803 | 0.10% | $33.00K | New | 0.00% |
| LPL Financial LLC | 14,889 | 0.10% | $31.42K | +250 | 0.00% |
| Raymond James Financial Inc | 14,864 | 0.10% | $31.36K | −470 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 13,318 | 0.09% | $29.00K | +3,096 | 0.00% |
| StoneX Group Inc. | 11,153 | 0.07% | $24.75K | New | 0.00% |
| Objectivity Squared, LLC | 10,915 | 0.07% | $23.03K | – | 0.01% |
| Farther Finance Advisors, LLC | 9,450 | 0.06% | $19.94K | +125 | 0.00% |
| UBS Group AG | 6,810 | 0.04% | $14.37K | −36,553 | 0.00% |
| Vanguard Global Advisers, LLC | 2,940 | 0.02% | $6.20K | – | 0.00% |
| Bay Harbor Wealth Management, LLC | 1,358 | 0.01% | $2.87K | New | 0.00% |
| IFS Advisors, LLC | 950 | 0.01% | $2.00K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 1M | 8.5% | 7 / 11 | 4 / 5 | 0M | 0M |
| Q1 2026 | 25 | 1M | 6.7% | 7 / 6 | 3 / 8 | 1M | 0M |
| Q4 2025 | 27 | 1M | 6.5% | 11 / 4 | 6 / 4 | 0M | 0M |
| Q3 2025 | 21 | 1M | 6.6% | 4 / 8 | 2 / 6 | 0M | 0M |
| Q2 2025 | 23 | 1M | 5.9% | 2 / 5 | 5 / 3 | 0M | 0M |
| Q1 2025 | 24 | 1M | 5.4% | 0 / 8 | 3 / 1 | 0M | 0M |
| Q4 2024 | 25 | 1M | 5.1% | 7 / 6 | 3 / 3 | 0M | 0M |
| Q3 2024 | 22 | 1M | 4.3% | 18 / 2 | 0 / 0 | 1M | 0M |
| Q2 2024 | 4 | 0M | 0.0% | 4 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
11 funds held DARE in Q2 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DARE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 471,486 | 3.08% | $994.84K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 161,385 | 1.06% | $340.52K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 78,050 | 0.51% | $174.05K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 45,289 | 0.30% | $95.56K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 32,473 | 0.21% | $72.41K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 15,326 | 0.10% | $34.18K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 8,006 | 0.05% | $16.89K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 7,571 | 0.05% | $16.88K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 2,978 | 0.02% | $6.28K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 626 | 0.00% | $1.32K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -600 | -0.00% | -$1.27K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sabrina Martucci Johnson | Chef Executive Officer, Director | 962,062 | 6.29% | Feb 20, 2026 |
| MarDee Haring-Layton | Chief Accounting Officer | – | – | Feb 2, 2026 |
| Jessica D. Grossman | Director | 26,066 | 0.17% | Jul 2, 2026 |
| Susan L. Kelley | Director | 23,696 | 0.15% | Jul 2, 2026 |
| Robin Joan Steele | Director | 293,226 | 1.92% | Jul 2, 2026 |
| William H. Rastetter | Director | 100,028 | 0.65% | Jul 2, 2026 |
| Gregory W. Matz | Director | 31,347 | 0.21% | Jul 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robin Joan Steele Director | Jun 30, 2026 | Award | +26,540 | – | – | 47,055 |
| William H. Rastetter Director | Jun 30, 2026 | Award | +38,862 | – | – | 39,721 |
| Jessica D. Grossman Director | Jun 30, 2026 | Award | +26,066 | – | – | 26,066 |
| Gregory W. Matz Director | Jun 30, 2026 | Award | +30,805 | – | – | 30,847 |
| Susan L. Kelley Director | Jun 30, 2026 | Award | +23,696 | – | – | 23,696 |
| Roger Hawley Director | Apr 11, 2019 | Buy | +454,545 | $1.10 | $500.00K | 944,956 |
| Roger Hawley Director | Jun 11, 2018 | Buy | +140,000 | $1.45 | $203.00K | 140,000 |
| Sabrina Martucci Johnson Chief Executive Officer, Director, 10% owner | Jul 19, 2017 | Award | +962,062 | – | – | 962,062 |
| Robin Joan Steele Director | Jul 19, 2017 | Award | +246,171 | – | – | 246,171 |
| Lisa Walters-Hoffert Chief Financial Officer | Jul 19, 2017 | Award | +443,512 | – | – | 443,512 |
| Roger Hawley Director | Jul 19, 2017 | Award | +182,697 | – | – | 182,697 |
| Roger Hawley Director | Jul 19, 2017 | Award | +307,714 | – | – | 490,411 |
| Paul A. Friedman Director | Apr 3, 2017 | Award | +10,273 | $0.73 | $7.50K | 18,819 |
| William H. Rastetter Director | Jan 3, 2017 | Award | +24,350 | $0.77 | $18.75K | 103,039 |
| David Ross Parkinson Director | Jan 3, 2017 | Award | +16,234 | $0.77 | $12.50K | 28,488 |
| David R. Walt Director | Jan 3, 2017 | Award | +14,935 | $0.77 | $11.50K | 193,700 |
| Paul A. Friedman Director | Jan 3, 2017 | Award | +4,870 | $0.77 | $3.75K | 8,546 |
| Stuart A. Arbuckle Director | Jan 3, 2017 | Award | +7,467 | $0.77 | $5.75K | 13,104 |
| William McKee Director | Jan 3, 2017 | Award | +1,948 | $0.77 | $1.50K | 3,418 |
| Christopherd T. Guiffre Chief Executive Officer, Director | Dec 31, 2016 | Award | +5,733 | $0.60 | $3.44K | 12,489 |
| David Ross Parkinson Director | Oct 3, 2016 | Award | +12,254 | $1.02 | $12.50K | 12,254 |
| William McKee Director | Oct 3, 2016 | Award | +1,470 | $1.02 | $1.50K | 1,470 |
| William H. Rastetter Director | Oct 3, 2016 | Award | +18,382 | $1.02 | $18.75K | 78,689 |
| David R. Walt Director | Oct 3, 2016 | Award | +11,274 | $1.02 | $11.50K | 178,765 |
| Stuart A. Arbuckle Director | Oct 3, 2016 | Award | +5,637 | $1.02 | $5.75K | 5,637 |
| Paul A. Friedman Director | Oct 3, 2016 | Award | +3,676 | $1.02 | $3.75K | 3,676 |
| Christopherd T. Guiffre Chief Executive Officer, Director | Jun 30, 2016 | Award | +3,999 | $1.80 | $7.20K | 6,756 |
| David R. Walt Director | Feb 22, 2016 | Buy | +591 | $2.09 | $1.24K | 167,491 |
| David R. Walt Director | Feb 19, 2016 | Buy | +1,700 | $2.08 | $3.54K | 166,900 |
| David R. Walt Director | Feb 18, 2016 | Buy | +4,500 | $2.09 | $9.41K | 165,200 |
| David R. Walt Director | Feb 17, 2016 | Buy | +4,460 | $2.12 | $9.46K | 160,700 |
| David R. Walt Director | Feb 16, 2016 | Buy | +4,500 | $2.00 | $9.00K | 156,240 |
| David R. Walt Director | Feb 12, 2016 | Buy | +4,311 | $2.00 | $8.62K | 151,740 |
| David R. Walt Director | Feb 11, 2016 | Buy | +4,350 | $2.03 | $8.83K | 147,429 |
| David R. Walt Director | Feb 10, 2016 | Buy | +4,500 | $2.08 | $9.36K | 143,079 |
| David R. Walt Director | Feb 9, 2016 | Buy | +4,500 | $2.08 | $9.36K | 138,579 |
| David R. Walt Director | Feb 8, 2016 | Buy | +4,500 | $2.22 | $9.99K | 134,079 |
| David R. Walt Director | Feb 5, 2016 | Buy | +4,500 | $2.29 | $10.31K | 129,579 |
| David R. Walt Director | Feb 4, 2016 | Buy | +4,063 | $2.31 | $9.39K | 125,079 |
| David R. Walt Director | Feb 3, 2016 | Buy | +4,018 | $2.27 | $9.12K | 121,016 |
| David R. Walt Director | Feb 2, 2016 | Buy | +4,395 | $2.37 | $10.42K | 116,998 |
| David R. Walt Director | Feb 1, 2016 | Buy | +4,500 | $2.37 | $10.67K | 112,603 |
| David R. Walt Director | Jan 29, 2016 | Buy | +1,200 | $2.41 | $2.89K | 108,103 |
| David R. Walt Director | Jan 28, 2016 | Buy | +4,500 | $2.45 | $11.03K | 106,903 |
| David R. Walt Director | Jan 27, 2016 | Buy | +4,500 | $2.47 | $11.12K | 102,403 |
| David R. Walt Director | Jan 26, 2016 | Buy | +4,300 | $2.44 | $10.49K | 97,903 |
| David R. Walt Director | Jan 25, 2016 | Buy | +4,500 | $2.35 | $10.58K | 93,603 |
| David R. Walt Director | Jan 22, 2016 | Buy | +4,500 | $2.24 | $10.08K | 89,103 |
| David R. Walt Director | Jan 21, 2016 | Buy | +4,500 | $2.32 | $10.44K | 84,603 |
| David R. Walt Director | Jan 20, 2016 | Buy | +4,500 | $2.35 | $10.58K | 80,103 |
| David R. Walt Director | Jan 19, 2016 | Buy | +4,400 | $2.52 | $11.09K | 75,603 |
| David R. Walt Director | Jan 15, 2016 | Buy | +4,172 | $2.42 | $10.10K | 71,203 |
| David R. Walt Director | Jan 14, 2016 | Buy | +4,400 | $2.64 | $11.62K | 67,031 |
| David R. Walt Director | Jan 13, 2016 | Buy | +4,384 | $2.69 | $11.79K | 62,631 |
| David R. Walt Director | Jan 12, 2016 | Buy | +4,300 | $2.89 | $12.43K | 58,247 |
| David R. Walt Director | Jan 11, 2016 | Buy | +4,355 | $2.86 | $12.46K | 53,947 |
| David R. Walt Director | Jan 8, 2016 | Buy | +4,500 | $2.87 | $12.92K | 49,592 |
| David R. Walt Director | Jan 7, 2016 | Buy | +4,300 | $2.87 | $12.34K | 45,092 |
| David R. Walt Director | Jan 6, 2016 | Buy | +4,500 | $3.03 | $13.64K | 40,792 |
| David R. Walt Director | Jan 5, 2016 | Buy | +4,301 | $3.06 | $13.16K | 36,292 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Dare Bioscience's stock actually held short. Settlement fails (shares not delivered on time) peaked at 99,984 shares on Aug 19, 2026 over the last 90 days.
See a number that looks wrong?